Nanobiotix Adr (NBTX)

Sep 20, 2024

Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.

Sep 20, 2024

Jun 16, 2024

Nanobiotix (NASDAQ:NBTX) Trading Down 14% - Defense World

Jun 16, 2024

Jun 15, 2024

Nanobiotix (NASDAQ:NBTX) Stock Price Down 14% - MarketBeat

Jun 15, 2024

May 24, 2024

Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat

May 24, 2024

May 23, 2024

Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 - Investing.com India

May 23, 2024

May 23, 2024

Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 By Investing.com - Investing.com

May 23, 2024

May 21, 2024

NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in ... - The Globe and Mail

May 21, 2024

May 16, 2024

Nanobiotix Announces Latest Share and Voting Rights UpdateTipRanks.com - TipRanks

May 16, 2024

May 15, 2024

Nanobiotix Prepares to Unveil Q1 2024 ResultsTipRanks.com - TipRanks

May 15, 2024

May 14, 2024

Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer StudyTipRanks.com - TipRanks

May 14, 2024

Apr 26, 2024

Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen PartnershipTipRanks.com - TipRanks

Apr 26, 2024

Apr 11, 2024

Nanobiotix Sa ADR Updates Share Capital InfoTipRanks.com - TipRanks

Apr 11, 2024

Apr 02, 2024

Nanobiotix Advances NBTXR3 for Lung Cancer TreatmentTipRanks.com - TipRanks

Apr 02, 2024

Jun 23, 2022

NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 - The Globe and Mail

Jun 23, 2022

Oct 24, 2021

NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC ... - The Globe and Mail

Oct 24, 2021

Jun 03, 2021

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire

Jun 03, 2021

Jun 01, 2021

NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive ... - The Globe and Mail

Jun 01, 2021

May 11, 2021

NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire

May 11, 2021

Dec 15, 2020

IPO Launch: Nanobiotix S.A. Pursues $96 Million IPOIPOs On TheStreetU.S. IPO Research & Opinion - TheStreet

Dec 15, 2020

Dec 11, 2020

NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat

Dec 11, 2020

Dec 11, 2020

Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat

Dec 11, 2020

Apr 07, 2020

Nanobiotix - Massachusetts Biotechnology Council

Apr 07, 2020